$CYCC News Article - Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor https://marketwirenews.com/news-releases/publ...66434.html
(0)
(0)
Cyclacel Pharmaceuticals Inc. (CYCC) Stock Research Links